Complications and status at last follow-up
| . | . | . | Regimen . | ||||
|---|---|---|---|---|---|---|---|
| Survival status and complications . | Entire cohort . | %* . | BuFlu±TT . | %* . | TreoFlu±TT . | %* . | P . |
| Status at last follow-up | |||||||
| Alive | 176 | 89.3 | 92 | 89.3 | 84 | 89.4 | 1.000 |
| Dead | 21 | 10.7 | 11 | 10.7 | 10 | 10.6 | |
| Causes of death | |||||||
| Infection | 8 | 38.1 | 5 | 45.5 | 3 | 30.0 | NA |
| GVHD | 8 | 38.1 | 2 | 18.2 | 6 | 60.0 | |
| Toxicity/organ damage | 1 | 4.8 | 1 | 9.1 | 0 | 0 | |
| Other | 4 | 19.0 | 3 | 27.3 | 1 | 10.0 | |
| VOD | |||||||
| No | 101 | 98.1 | 52 | 96.3 | 49 | 100.0 | .496† |
| Yes | 2‡ | 1.9 | 2 | 3.7 | 0 | 0.0 | |
| Missing | 94 | ||||||
| Disappearance of all WAS symptoms | |||||||
| Yes | 120 | 81.6 | 67 | 87.0 | 53 | 75.7 | .090 |
| No | 26 | 17.7 | 10 | 13.0 | 16 | 22.9 | |
| Missing | 51 | 26 | 25 | ||||
| . | . | . | Regimen . | ||||
|---|---|---|---|---|---|---|---|
| Survival status and complications . | Entire cohort . | %* . | BuFlu±TT . | %* . | TreoFlu±TT . | %* . | P . |
| Status at last follow-up | |||||||
| Alive | 176 | 89.3 | 92 | 89.3 | 84 | 89.4 | 1.000 |
| Dead | 21 | 10.7 | 11 | 10.7 | 10 | 10.6 | |
| Causes of death | |||||||
| Infection | 8 | 38.1 | 5 | 45.5 | 3 | 30.0 | NA |
| GVHD | 8 | 38.1 | 2 | 18.2 | 6 | 60.0 | |
| Toxicity/organ damage | 1 | 4.8 | 1 | 9.1 | 0 | 0 | |
| Other | 4 | 19.0 | 3 | 27.3 | 1 | 10.0 | |
| VOD | |||||||
| No | 101 | 98.1 | 52 | 96.3 | 49 | 100.0 | .496† |
| Yes | 2‡ | 1.9 | 2 | 3.7 | 0 | 0.0 | |
| Missing | 94 | ||||||
| Disappearance of all WAS symptoms | |||||||
| Yes | 120 | 81.6 | 67 | 87.0 | 53 | 75.7 | .090 |
| No | 26 | 17.7 | 10 | 13.0 | 16 | 22.9 | |
| Missing | 51 | 26 | 25 | ||||
VOD, veno-occlusive disease; NA, not applicable.
Percentages are calculated within the nonmissing.
This P value is provided for descriptive purposes only, even though it is statistically inadequate because one category has a value of “0.” Due to the nature of this study, data on immune reconstitution, revaccination rates, and time to immunoglobulin independence were not available.
One moderate, one severe VOD. The patient with severe VOD died.